Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2375]
News [3438]
Articles [281]
Editorials [30]
Conferences [171]
elearning [101]
Role of molecular diagnostics in prostate cancer
Dr Elena Castro and Dr Shahneen Sandhu
Role of molecular diagnostics in prostate cancer ( Dr Elena Castro and Dr Shahneen Sandhu )
2 Oct 2019
Key developments in pancreatic cancer from ESMO 2019
Prof Eileen O'Reilly and Dr Ian Chau
Key developments in pancreatic cancer from ESMO 2019 ( Prof Eileen O'Reilly and Dr Ian Chau )
2 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
30 Sep 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF...
Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
30 Sep 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA
MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )
29 Sep 2019
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...
Prof George Sledge - Stanford Health Care, Stanford, USA
Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
Comment: Front-line osimertinib significantly lengthens overall survival in...
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre...
Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium
Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )
25 Sep 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation